Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7PQIK)

Drug Name
Nitrofurantoin Drug Info
Synonyms
Alfuran; Benkfuran; Berkfuran; Berkfurin; Ceduran; Chemiofuran; Cistofuran; Cyantin; Cystit; Dantafur; Furabid; Furachel; Furadantin; Furadantine; Furadantoin; Furadoine; Furadonin; Furadonine; Furadoninum; Furadontin; Furalan; Furaloid; Furantoin; Furatoin; Furedan; Furina; Furobactina; Furodantin; Furophen; Gerofuran; Ituran; Macpac; Macrobid; Macrodantin; Macrodantina; Macrofuran; Macrofurin; NITROFURANTION; Nierofu; Nifurantin; Nifuretten; Nitoin; Nitrex; Nitrofuradantin; Nitrofurantoina; Nitrofurantoine; Nitrofurantoinum; Novofuran; Orafuran; Parfuran; Phenurin; PiyEloseptyl; Siraliden; Trantoin; Uerineks; Urantoin; Urizept; Urodil; Urodin; Urofuran; Urofurin; Urolisa; Urolong; Welfurin; Zoofurin; Fua Med; Furadantin Retard; Furadantina MC; Furadantine mc; Furophen T; NITROFURANTOIN MACROCRYSTALLINE; Nitrofurantoina [DCIT]; Fua-med; Fur-ren; Furadantin (TN); Furadantine-MC; Macrobid (TN); Macrodantin (TN); N-Toin; ND-3320; ND-7248; NITROFURANTOIN, MACROCRYSTALLINE; Nitro Macro (TN); Nitrofur-C; Nitrofurantoine [INN-French]; Nitrofurantoinum [INN-Latin]; Ro-Antoin; Urantoin (TN); Uro-Selz; Uro-Tablinen; Uro-tablineu; Usaf ea-2; Nitrofurantoin (JAN/USP/INN); Nitrofurantoin [USAN:INN:BAN:JAN]; N-(5-Nitrofurfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; N-(5-nitro-2-furfurylidene)-1-aminohyda ntoin; 1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; 1-(5-Nitro-2-furfurylideneamino)hydantoin; 1-[(5-:nitrofurfurylidene)amino]hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; 1-{[(1E)-(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; 5-Nitrofurantoin
Indication
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Approved [1]
Therapeutic Class
Antiinfective Agents
Cross-matching ID
PubChem CID
6604200
ChEBI ID
CHEMBL572
CAS Number
CAS 67-20-9
TTD Drug ID
DM7PQIK
VARIDT Drug ID
DR00886
INTEDE Drug ID
DR1169
ACDINA Drug ID
D00475

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Bacterial Deoxyribonucleic acid (Bact DNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metronidazole DMTIVEN Abscess Approved [16]
Clofazimine DMEBOFW Crohn disease DD70 Approved [17]
Hydroxystilbamidine Isethionate DMR5QS6 Blastomycosis 1F22 Approved [18]
Furazolidone DM3P6V7 Diarrhea ME05.1 Approved [19]
Proflavine DMF1X5P Sepsis 1G40-1G41 Approved [20]
MGB-BP-3 DMPBTVK Clostridium infection 1A04 Phase 2 [21]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Transported By Breast cancer resistance protein (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [22]
Methotrexate DM2TEOL Anterior urethra cancer Approved [23]
Folic Acid DMEMBJC Colorectal carcinoma Approved [24]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [25]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [26]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [27]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [28]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [27]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [29]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By NADPH-cytochrome P450 reductase (CPR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [31]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [32]
Tacrolimus DMZ7XNQ Graft-versus-host disease 4B24 Approved [33]
Benzphetamine DMIJATC Obesity 5B81 Approved [34]
Nilutamide DMFN07X Prostate cancer 2C82.0 Approved [35]
Menadiol sodium diphosphate DMP9N85 Coagulation defect 3B10.0 Approved [36]
Amrubicin DM6SGUB Small-cell lung cancer 2C25.Y Phase 3 [37]
Nitrobenzodiazepine DM254EW N. A. N. A. Investigative [38]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Metabolized By Nitroreductase (NTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitrazepam DMEGIQ6 Epilepsy 8A60-8A68 Approved [39]
P-nitrobenzoic acid DMVJUOZ N. A. N. A. Investigative [10]
P-nitrobenzoic acid DMVJUOZ N. A. N. A. Investigative [10]
Metronidazole DMTIVEN Abscess Approved [40]
P-nitrobenzoic acid DMVJUOZ N. A. N. A. Investigative [10]
P-nitrobenzoic acid DMVJUOZ N. A. N. A. Investigative [10]
Metronidazole DMTIVEN Abscess Approved [9]
Nitrofurazone DMSM2KE Skin burns ME65.0 Approved [9]
Metronidazole DMTIVEN Abscess Approved [9]
Nitrofurazone DMSM2KE Skin burns ME65.0 Approved [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By NADPH-dependent oxidoreductase (nfrA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Riboflavin DM8YMWE Acne vulgaris ED80 Approved [5]
Nitrofurazone DMSM2KE Skin burns ME65.0 Approved [5]
Drug(s) Metabolized By NADPH-dependent nitroreductase (nfrA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Riboflavin DM8YMWE Acne vulgaris ED80 Approved [7]
Nitrofurazone DMSM2KE Skin burns ME65.0 Approved [7]
Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Testosterone DM7HUNW Hot flushes GA30 Approved [41]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [41]
Gefitinib DM15F0X Colon adenocarcinoma Approved [42]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [43]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [44]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [45]
Methotrexate DM2TEOL Anterior urethra cancer Approved [46]
Quercetin DM3NC4M Obesity 5B81 Approved [47]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [48]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bile salt export pump (ABCB11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [50]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [12]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [12]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [51]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [50]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [12]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [15]
Gefitinib DM15F0X Colon adenocarcinoma Approved [50]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [52]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Paclitaxel DMLB81S Breast carcinoma Approved [53]
Verapamil DMA7PEW Angina pectoris BA40 Approved [54]
Methysergide DM1EF73 Migraine 8A80 Approved [15]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [55]
Methotrexate DM2TEOL Anterior urethra cancer Approved [56]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [15]
Quercetin DM3NC4M Obesity 5B81 Approved [57]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [58]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [59]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [60]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Heat shock factor protein 1 (HSF1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [61]
SPI-1005 DM6XFHS Reperfusion injury ND56.Z Approved [14]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [14]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [62]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [63]
Ceftazidime DM41GRA Bacteremia 1A73 Approved [14]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [64]
Chlorpheniramine DM5URA2 Allergic rhinitis CA08.0 Approved [14]
Ethacrynic acid DM60QMR Edema MG29 Approved [14]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Deoxyribonucleic acid (Bact DNA) TTS1W4A NOUNIPROTAC Breaker [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Substrate [4]
NADPH-dependent oxidoreductase (nfrA) DE82GV7 NRFA_STAA8 Substrate [5] , [6]
NADPH-dependent nitroreductase (nfrA1) DE21PLI NFRA1_BACSU Substrate [7] , [8]
Nitroreductase (NTR) DEUW4J0 A0A376H6M5_ENTGA Substrate [9]
Nitroreductase (NTR) DEP7ECA B1R7B9_CLOPF Substrate [10]
Nitroreductase (NTR) DE5LYXF A0A2X3BKF5_CLOSG Substrate [11] , [10]
Nitroreductase (NTR) DE3U2Y6 A0A377KR04_ENTCA Substrate [9]
Nitroreductase (NTR) DEAVXGM A0A412R9E4_9FIRM Substrate [10]
Nitroreductase (NTR) DE7XBKW A0A174SJF2_9CLOT Substrate [10]
Nitroreductase (NTR) DEH3ABM A0A351QTB1_CLOSP Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [12]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Regulation of Drug Effects [13]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Gene/Protein Processing [14]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Gene/Protein Processing [15]

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009175.
2 On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14.
3 The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol. 2005 May;67(5):1758-64.
4 Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79.
5 Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev. 2008 May;32(3):474-500.
6 The human gut microbiota: metabolism and perspective in obesity. Gut Microbes. 2018 Jul 4;9(4):308-325.
7 Conversion of NfsA, the major Escherichia coli nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in Vibrio harveyi, by a single amino acid substitution. J Bacteriol. 1998 Jan;180(2):422-5.
8 Bacillus subtilis isolated from the human gastrointestinal tract. Res Microbiol. 2009 Mar;160(2):134-43.
9 Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
10 Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
11 Biotransformation of 1-nitropyrene in intestinal anaerobic bacteria. Microbiol Immunol. 1982;26(11):993-1005.
12 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
13 Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos. 2007 Feb;35(2):268-74.
14 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
15 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
16 DNA breakage due to metronidazole treatment. Mutat Res. 2001 Jul 1;478(1-2):153-8.
17 The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4.
18 Interaction between hydroxystilbamidine and DNA. I. Binding isotherms and thermodynamics of the association. Biochim Biophys Acta. 1975 Sep 12;407(1):24-42.
19 Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5.
20 Interaction of small molecules with double-stranded RNA: spectroscopic, viscometric, and calorimetric study of hoechst and proflavine binding to PolyCG structures. DNA Cell Biol. 2009 Apr;28(4):209-19.
21 Clinical pipeline report, company report or official report of MGB Biopharma.
22 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
23 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
24 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
25 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
26 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
27 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
28 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
29 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
30 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
31 Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
32 Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
33 Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
34 On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403.
35 Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol. 1992 Feb 4;43(3):654-7.
36 Creatinine sulfate/esculoside/hesperidin methyl chalcone/menadiol sodium phosphate/tranexamic acid actions.
37 Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33.
38 Flavin-containing reductase: new perspective on the detoxification of nitrobenzodiazepine. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):967-81.
39 Reduction of nitrazepam by Clostridium leptum, a nitroreductase-producing bacterium isolated from the human intestinal tract. Clin Infect Dis. 1997 Sep;25 Suppl 2:S121-2.
40 Acetamide--a metabolite of metronidazole formed by the intestinal flora. Biochem Pharmacol. 1979 Dec 15;28(24):3611-5.
41 Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
42 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
43 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
44 ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
45 Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
46 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
47 Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
48 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
49 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
50 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
51 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
52 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
53 [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
54 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
55 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
56 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
57 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
58 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
59 Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
60 Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
61 NRF2 transcriptionally activates the heat shock factor 1 promoter under oxidative stress and affects survival and migration potential of MCF7 cells. J Biol Chem. 2018 Dec 14;293(50):19303-19316. doi: 10.1074/jbc.RA118.003376. Epub 2018 Oct 11.
62 Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
63 Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
64 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.